Pulmatrix to Regain Full Rights to PUR1800 and Narrow Spectrum Kinase Inhibitor PortfolioPRNewsWire • 04/12/21
Pulmatrix Announces $40 Million Registered Direct Offering Priced At-the-Market under Nasdaq RulesPRNewsWire • 02/11/21
Pulmatrix Announces Publication Demonstrating Reduction of Bioaerosols with FEND, an OTC Nasal Hygiene Product Designed to Cleanse Airways of Airborne ParticlesPRNewsWire • 09/30/20
Pulmatrix's stock rockets after deal with Cipla Technologies to develop, commercialize asthma treatmentMarket Watch • 04/01/19